Syntara Ltd (SNT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Syntara Ltd (SNT) has a cash flow conversion efficiency ratio of -0.694x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-11.12 Million ≈ $-7.86 Million USD) by net assets (AU$16.02 Million ≈ $11.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Syntara Ltd - Cash Flow Conversion Efficiency Trend (2004–2023)
This chart illustrates how Syntara Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Syntara Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Syntara Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syntara Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Curo Holdings Co. Ltd
KQ:051780
|
-0.068x |
|
Santierul Naval Orsova SA
RO:SNO
|
0.014x |
|
Projektengagemang Sweden AB (publ)
ST:PENG-B
|
0.038x |
|
EasyJet PLC
LSE:EZJ
|
0.265x |
|
SWISS PROPERTIES INV.100
F:SR1
|
N/A |
|
Fridenson
TA:FRDN
|
0.055x |
|
Hulamin
JSE:HLM
|
0.009x |
|
Zanaga Iron Ore Company Limited
F:6ZA
|
0.001x |
Annual Cash Flow Conversion Efficiency for Syntara Ltd (2004–2023)
The table below shows the annual cash flow conversion efficiency of Syntara Ltd from 2004 to 2023. For the full company profile with market capitalisation and key ratios, see Syntara Ltd (SNT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | AU$9.56 Million ≈ $6.76 Million |
AU$-7.28 Million ≈ $-5.15 Million |
-0.761x | +49.55% |
| 2022-06-30 | AU$10.80 Million ≈ $7.64 Million |
AU$-16.30 Million ≈ $-11.54 Million |
-1.509x | -239.75% |
| 2021-06-30 | AU$2.85 Million ≈ $2.01 Million |
AU$3.07 Million ≈ $2.17 Million |
1.080x | +111.63% |
| 2020-06-30 | AU$1.43 Million ≈ $1.01 Million |
AU$-13.28 Million ≈ $-9.40 Million |
-9.283x | -594.61% |
| 2019-06-30 | AU$14.81 Million ≈ $10.48 Million |
AU$-19.80 Million ≈ $-14.01 Million |
-1.336x | -221.73% |
| 2018-06-30 | AU$11.12 Million ≈ $7.87 Million |
AU$12.21 Million ≈ $8.64 Million |
1.098x | +125.33% |
| 2017-06-30 | AU$3.52 Million ≈ $2.49 Million |
AU$-15.26 Million ≈ $-10.80 Million |
-4.335x | -656.57% |
| 2016-06-30 | AU$20.93 Million ≈ $14.81 Million |
AU$-11.99 Million ≈ $-8.48 Million |
-0.573x | -195.54% |
| 2015-06-30 | AU$36.32 Million ≈ $25.70 Million |
AU$21.78 Million ≈ $15.41 Million |
0.600x | +138.51% |
| 2014-06-30 | AU$18.07 Million ≈ $12.78 Million |
AU$-28.13 Million ≈ $-19.91 Million |
-1.557x | -198.78% |
| 2013-06-30 | AU$67.89 Million ≈ $48.04 Million |
AU$-35.38 Million ≈ $-25.04 Million |
-0.521x | -50.03% |
| 2012-06-30 | AU$109.80 Million ≈ $77.69 Million |
AU$-38.14 Million ≈ $-26.99 Million |
-0.347x | +34.15% |
| 2011-06-30 | AU$70.83 Million ≈ $50.12 Million |
AU$-37.37 Million ≈ $-26.44 Million |
-0.528x | -52.90% |
| 2010-06-30 | AU$115.02 Million ≈ $81.38 Million |
AU$-39.68 Million ≈ $-28.08 Million |
-0.345x | -79.48% |
| 2009-06-30 | AU$137.69 Million ≈ $97.43 Million |
AU$-26.47 Million ≈ $-18.73 Million |
-0.192x | -21.48% |
| 2008-06-30 | AU$119.12 Million ≈ $84.29 Million |
AU$-18.85 Million ≈ $-13.34 Million |
-0.158x | +41.47% |
| 2007-06-30 | AU$76.56 Million ≈ $54.17 Million |
AU$-20.70 Million ≈ $-14.64 Million |
-0.270x | -94.07% |
| 2006-06-30 | AU$98.89 Million ≈ $69.97 Million |
AU$-13.78 Million ≈ $-9.75 Million |
-0.139x | +46.58% |
| 2005-06-30 | AU$35.57 Million ≈ $25.17 Million |
AU$-9.27 Million ≈ $-6.56 Million |
-0.261x | -50.10% |
| 2004-06-30 | AU$26.78 Million ≈ $18.95 Million |
AU$-4.65 Million ≈ $-3.29 Million |
-0.174x | -- |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more